Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsInvestigators showed that pharmacological inhibition of BRAF-V600E or ERK1/2 in melanoma cells increased PARK2 expression.
[Journal of Biological Chemistry]
6807162 {6807162:I4DHC8YY} apa 50 1 154253 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-946055b78cd1516d36a1213cd016f7b6%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22I4DHC8YY%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montagnani%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-16%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMontagnani%2C%20V.%2C%20Maresca%2C%20L.%2C%20Apollo%2C%20A.%2C%20Pepe%2C%20S.%2C%20Carr%2C%20R.%20M.%2C%20Fernandez-Zapico%2C%20M.%20E.%2C%20%26amp%3B%20Stecca%2C%20B.%20%282020%29.%20E3%20ubiquitin%20ligase%20PARK2%2C%20an%20inhibitor%20of%20melanoma%20cell%20growth%2C%20is%20repressed%20by%20the%20oncogenic%20ERK1%5C%2F2-ELK1%20transcriptional%20axis.%20%3Ci%3EJournal%20of%20Biological%20Chemistry%3C%5C%2Fi%3E%2C%20jbc.RA120.014615.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.RA120.014615%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.RA120.014615%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3DI4DHC8YY%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22E3%20ubiquitin%20ligase%20PARK2%2C%20an%20inhibitor%20of%20melanoma%20cell%20growth%2C%20is%20repressed%20by%20the%20oncogenic%20ERK1%5C%2F2-ELK1%20transcriptional%20axis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentina%22%2C%22lastName%22%3A%22Montagnani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22Maresca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Apollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Pepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryan%20M.%22%2C%22lastName%22%3A%22Carr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20E.%22%2C%22lastName%22%3A%22Fernandez-Zapico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Stecca%22%7D%5D%2C%22abstractNote%22%3A%22Malignant%20melanoma%2C%20the%20most%20aggressive%20form%20of%20skin%20cancer%2C%20is%20characterized%20by%20high%20prevalence%20of%20BRAF%5C%2FNRAS%20mutations%20and%20hyperactivation%20of%20extracellular%20signal-regulated%20kinase%201%20and%202%20%28ERK1%5C%2F2%29%2C%20mitogen-activated%20protein%20kinases%20%28MAPK%29%2C%20leading%20to%20uncontrolled%20melanoma%20growth.%20Efficacy%20of%20current%20targeted%20therapies%20against%20mutant%20BRAF%20or%20MEK1%5C%2F2%20have%20been%20hindered%20by%20existence%20of%20innate%20or%20development%20of%20acquired%20resistance.%20Therefore%2C%20a%20better%20understanding%20of%20the%20mechanisms%20controlled%20by%20MAPK%20pathway%20driving%20melanogenesis%20will%20help%20develop%20new%20treatment%20approaches%20targeting%20this%20oncogenic%20cascade.%20Here%2C%20we%20identify%20E3%20ubiquitin%20ligase%20PARK2%20as%20a%20direct%20target%20of%20ELK1%2C%20a%20known%20transcriptional%20effector%20of%20MAPK%20signaling%20in%20melanoma%20cells.%20We%20show%20that%20pharmacological%20inhibition%20of%20BRAF-V600E%20or%20ERK1%5C%2F2%20in%20melanoma%20cells%20increases%20PARK2%20expression.%20PARK2%20overexpression%20reduces%20melanoma%20cell%20growth%20in%20vitro%20and%20in%20vivo%20and%20induces%20apoptosis.%20Conversely%2C%20its%20genetic%20silencing%20increases%20melanoma%20cell%20proliferation%20and%20reduces%20cell%20death.%20Further%2C%20we%20demonstrate%20that%20ELK1%20is%20required%20by%20the%20BRAF-ERK1%5C%2F2%20pathway%20to%20repress%20PARK2%20expression%20and%20promoter%20activity%20in%20melanoma%20cells.%20Clinically%2C%20PARK2%20is%20highly%20expressed%20in%20wild%20type%20BRAF%20and%20NRAS%20melanomas%2C%20but%20it%20is%20expressed%20at%20low%20levels%20in%20melanomas%20carrying%20BRAF%5C%2FNRAS%20mutations.%20Overall%2C%20our%20data%20provide%20new%20insights%20into%20the%20tumor%20suppressive%20role%20of%20PARK2%20in%20malignant%20melanoma%20and%20uncover%20a%20novel%20mechanism%20for%20the%20negative%20regulation%20of%20PARK2%20via%20the%20ERK1%5C%2F2-ELK1%20axis.%20These%20findings%20suggest%20that%20reactivation%20of%20PARK2%20may%20be%20a%20promising%20therapeutic%20approach%20to%20counteract%20melanoma%20growth.%22%2C%22date%22%3A%222020-09-16%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1074%5C%2Fjbc.RA120.014615%22%2C%22ISSN%22%3A%220021-9258%2C%201083-351X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.jbc.org%5C%2Fcontent%5C%2Fearly%5C%2F2020%5C%2F09%5C%2F16%5C%2Fjbc.RA120.014615%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222020-09-17T21%3A51%3A45Z%22%7D%7D%5D%7D
Montagnani, V., Maresca, L., Apollo, A., Pepe, S., Carr, R. M., Fernandez-Zapico, M. E., & Stecca, B. (2020). E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis. Journal of Biological Chemistry, jbc.RA120.014615. https://doi.org/10.1074/jbc.RA120.014615 Cite
